BeyondSpring Inc.
NASDAQ:BYSI
Overview | Financials
Company Name | BeyondSpring Inc. |
Symbol | BYSI |
Currency | USD |
Price | 1.661 |
Market Cap | 66,926,874 |
Dividend Yield | 0% |
52-week-range | 0.778 - 4 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Lan Huang Ph.D. |
Website | https://www.beyondspringpharma.com |
An error occurred while fetching data.
About BeyondSpring Inc.
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD